King Faisal Specialist Hospital, Riyadh – United Arab Emirates
About Dr. Saud Alhayli
Dr. Saud Alhayli is a Consultant in the Department of Hematology and Cellular Therapy, specialising in lymphoma and multiple myeloma — a trusted lymphoma and myeloma specialist in Riyadh, Saudi Arabia. His practice combines systemic therapy, cellular therapy coordination, and participation in national myeloma guidelines.
- Consultant, Hematology, Stem Cell Transplant & Cellular Therapy Department
- Co-author on the 2025 Saudi Myeloma Working Group Guideline
- Senior co-author on the 2025 Hematology Reports review of rare plasma cell disorders
- Contributor to national CAR-T therapy outcomes data for DLBCL
- Active author on Hodgkin’s lymphoma post-transplant management research
Qualifications & Credentials
Medical Degrees
- MBBS — Information not publicly available.
- Internal Medicine Residency — Information not publicly available.
- Adult Hematology Specialty Training — Information not publicly available.
Fellowships & Special Training
- Adult Hematology / Cellular Therapy Fellowship — King Faisal Specialist Hospital & Research Centre, Riyadh
Certifications & Accreditations
- Saudi Commission for Health Specialties (SCFHS) registration
- Information not publicly available.
Areas of Expertise
Major Conditions Treated
- Multiple Myeloma (IgG, IgA, IgD, IgE, IgM, non-secretory)
- Plasma Cell Leukemia
- Heavy Chain Disease
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Hodgkin Lymphoma (relapsed/refractory)
- MGUS (Monoclonal Gammopathy of Undetermined Significance)
Sub-specialties
- Multiple Myeloma & Rare Plasma Cell Disorders: Expertise in IgD, IgE, and IgM myeloma, non-secretory myeloma, plasma cell leukemia, and heavy chain disease — critical for patients seeking best myeloma treatment in Saudi Arabia.
- CD19 CAR-T Cell Therapy Coordination: Co-investigator on single-centre CAR-T outcomes in relapsed/refractory DLBCL.
- Cellular Therapy Post-Transplant Management: Experienced in immune checkpoint inhibitor restoration post allogeneic stem cell transplant.
Advanced Procedures & Treatments
- Induction Chemotherapy for Multiple Myeloma
- Autologous Stem Cell Transplantation Support
- CD19 CAR-T Cell Therapy (Tisagenlecleucel)
- Relapsed/Refractory Myeloma Salvage Regimens
- Proteasome Inhibitor Therapy (Bortezomib, Carfilzomib)
- Immunomodulatory Drug Therapy (Lenalidomide, Pomalidomide)
- Monoclonal Antibody Therapy (Daratumumab, Isatuximab)
Professional Experience
Current Affiliation
- King Faisal Specialist Hospital & Research Centre, Riyadh, Saudi Arabia — Consultant, Department of Hematology and Cellular Therapy (Current)
Past Affiliations
- King Faisal Specialist Hospital & Research Centre, Riyadh — Fellow, Adult Hematology
Academic & Research Roles
- Member — Saudi Myeloma Working Group
Key Achievements
- Co-author on the Saudi Myeloma Working Group Guideline (2025)
- Co-author on the Saudi national consensus on newly diagnosed multiple myeloma management
- Contributor to published CAR-T outcomes in DLBCL at a regional centre of excellence
Awards & Recognitions
National & International Awards
- Information not publicly available.
Professional Memberships
- Saudi Myeloma Working Group
- Saudi Society of Blood Disorders — Information not publicly available.
Research & Publications
Published Papers (Selected)
- Hanbali A, Alamer A, Alhayli S. Uncommon Entities, Uncommon Challenges: A Review of Rare Plasma Cell Disorders. Hematol Rep. 2025;17(4):31. DOI: 10.3390/hematolrep17040031
- Alhejazi A, Alotaibi G, Al Saleh A et al. Guidelines on Management of Multiple Myeloma in the Relapsed/Refractory Setting: The Saudi Myeloma Working Group Guideline. Clin Lymphoma Myeloma Leuk. 2025;25(10):e756-e765. DOI: 10.1016/j.clml.2025.05.005
- Farhan K, Albabtain A, Alhayli S, Rasheed W, Alshaibani A, Chaudhri N, Alahmari A, Aljurf M, El Fakih R. Successful Restoration of Nivolumab Efficacy Post Allogeneic Stem Cell Transplantation in Hodgkin's Lymphoma. Blood. 2022;140(Suppl 1):12048-12049. DOI: 10.1182/blood-2022-158953
Ongoing Research & Clinical Interests
- Rare plasma cell disorders (IgD/IgE/IgM myeloma, plasma cell leukemia)
- CAR-T cell therapy outcomes in NHL
- Post-transplant immunotherapy
- Saudi national myeloma guidelines
Estimated Treatment Costs
| Procedure / Consultation | Estimated Cost (SAR) | Estimated Cost (USD) |
|---|---|---|
| Hematology Consultation | SAR 500 – SAR 1,500 | $135 – $400 |
| Multiple Myeloma Induction Therapy (per cycle) | SAR 20,000 – SAR 60,000 | $5,300 – $16,000 |
| Autologous SCT (myeloma) | SAR 150,000 – SAR 300,000 | $40,000 – $80,000 |
| CD19 CAR-T Cell Therapy | SAR 1,300,000 – SAR 1,800,000 | $347,000 – $480,000 |
| Daratumumab / Isatuximab Therapy (per cycle) | SAR 25,000 – SAR 70,000 | $6,700 – $18,700 |
Frequently Asked Questions
1. What advanced technologies does Dr. Saud Alhayli use as a Hematologist?
Dr. Saud Alhayli uses the latest myeloma and lymphoma therapies including proteasome inhibitors, immunomodulatory drugs, CD38 monoclonal antibodies (Daratumumab, Isatuximab), CD19 CAR-T cell therapy for lymphoma, and post-transplant immune checkpoint restoration strategies. International myeloma and lymphoma second opinions can be arranged via Cancer Rounds.
2. What conditions does Dr. Saud Alhayli specialize in treating?
Dr. Saud Alhayli specialises in multiple myeloma (including rare IgD, IgE, and IgM subtypes, non-secretory myeloma, and plasma cell leukemia), diffuse large B-cell lymphoma, Hodgkin lymphoma, MGUS, and heavy chain disease. He is a senior myeloma and lymphoma consultant in Riyadh for complex and relapsed cases.
3. How do I book an appointment with Dr. Saud Alhayli?
Appointments with Dr. Saud Alhayli can be booked directly through the Cancer Rounds website or by contacting their international patient department for priority scheduling.
4. Can international patients receive treatment from Dr. Saud Alhayli?
Yes. Cancer Rounds provides full assistance for international patients seeking treatment from Dr. Saud Alhayli, including Saudi Arabia medical visa invitation letters, airport transfers, and local accommodation coordination in Riyadh.
5. What support is available for international patients?
International patients benefit from a dedicated concierge service provided by Cancer Rounds, including language interpretation (Arabic, English, and more), financial counselling, and pre-travel virtual consultations to review medical records before arrival in Riyadh.
6. Does Dr. Saud Alhayli offer second opinions as a Hematologist?
Yes. Second opinion consultations can be arranged via Cancer Rounds for patients who wish to review their diagnosis or treatment plan with Dr. Saud Alhayli, an expert Hematologist in Riyadh, Saudi Arabia.
